SEARCH:   Advanced

Blood, 1 March 2004, Vol. 103, No. 5, pp. 1641-1646. Prepublished online as a Blood First Edition Paper on November 6, 2003; DOI 10.1182/blood-2003-07-2233. This Article Full Text (PDF) All Versions of this Article: 2003-07-2233v1 103/5/1641    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Dingli, D. Articles by Russell, S. J Search for Related Content PubMed PubMed Citation Articles by Dingli, D. Articles by Russell, S. J Social Bookmarking                   What's this? Submitted July 21, 2003 Accepted September 17, 2003 Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter David Dingli, Kah-Whye Peng, Mary E Harvey, Philip R Greipp, Michael K O'Connor, Roberto Cattaneo, John C Morris, and Stephen J Russell* Molecular Medicine Program, Mayo Foundation, Rochester, MN, USA; Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA Molecular Medicine Program, Mayo Foundation, Rochester, MN, USA Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA Department of Radiology, Mayo Clinic, Rochester, MN, USA Division of Endocrinology and Metabolism, Mayo Clinic, Rochester, MN, USA * Corresponding author; email: sjr{at}mayo.edu. The Edmonston vaccine strain of measles virus (MV-Edm) propagates efficiently in a broad range of human tumor cells, killing them selectively. However, the oncolytic potency of MV-Edm in different human tumor xenograft therapy models is highly variable and there is no convenient way to map the distribution of virus-infected tissues in vivo. To enhance the oncolytic potency of MV-Edm against radiosensitive malignancies and to facilitate noninvasive imaging of infected tissues, we generated a recombinant MV-Edm encoding the human thyroidal iodide symporter (NIS). MV-NIS replicated almost as efficiently as unmodified MV-Edm and human tumor cells efficiently concentrated radioiodine when infected with MV-NIS. Intratumoral spread of MV-NIS was noninvasively demonstrated by serial gamma-camera imaging of 123I uptake both in MV-sensitive KAS-6/1 myeloma xenografts, which regressed completely after a single intravenous dose of MV-NIS, and in MM1 myeloma xenografts which were unresponsive to MV-NIS therapy. However, MV-resistant MM1 tumors regressed completely when 131I was administered 9 days after a single intravenous injection of MV-NIS (radiovirotherapy). 131I alone had no effect on MM1 tumor growth. While the potential hemopoietic toxicity of this new therapy requires further evaluation, image-guided radiovirotherapy is a promising new approach to the treatment of multiple myeloma, an incurable but highly radiosensitive plasma cell malignancy. Testing in other radiosensitive cancers is warranted. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: E. K. Mader, Y. Maeyama, Y. Lin, G. W. Butler, H. M. Russell, E. Galanis, S. J. Russell, A. B. Dietz, and K.-W. Peng Mesenchymal Stem Cell Carriers Protect Oncolytic Measles Viruses from Antibody Neutralization in an Orthotopic Ovarian Cancer Therapy Model Clin. Cancer Res., December 1, 2009; 15(23): 7246 - 7255. [Abstract] [Full Text] [PDF] I. Peerlinck, A. Merron, P. Baril, S. Conchon, P. Martin-Duque, C. Hindorf, J. Burnet, M. Quintanilla, M. Hingorani, R. Iggo, et al. Targeted Radionuclide Therapy Using a Wnt-Targeted Replicating Adenovirus Encoding the Na/I Symporter Clin. Cancer Res., November 1, 2009; 15(21): 6595 - 6601. [Abstract] [Full Text] [PDF] K. Klutz, V. Russ, M. J. Willhauck, N. Wunderlich, C. Zach, F. J. Gildehaus, B. Goke, E. Wagner, M. Ogris, and C. Spitzweg Targeted Radioiodine Therapy of Neuroblastoma Tumors following Systemic Nonviral Delivery of the Sodium Iodide Symporter Gene Clin. Cancer Res., October 1, 2009; 15(19): 6079 - 6086. [Abstract] [Full Text] [PDF] H.-D. Hummel, G. Kuntz, S. J. Russell, T. Nakamura, A. Greiner, H. Einsele, and M. S. Topp Genetically engineered attenuated measles virus specifically infects and kills primary multiple myeloma cells J. Gen. Virol., March 1, 2009; 90(3): 693 - 701. [Abstract] [Full Text] [PDF] S. K. Carlson, K. L. Classic, E. M. Hadac, D. Dingli, C. E. Bender, B. J. Kemp, and S. J. Russell Quantitative Molecular Imaging of Viral Therapy for Pancreatic Cancer Using an Engineered Measles Virus Expressing the Sodium-Iodide Symporter Reporter Gene Am. J. Roentgenol., January 1, 2009; 192(1): 279 - 287. [Abstract] [Full Text] [PDF] M. Dayem, C. Basquin, V. Navarro, P. Carrier, R. Marsault, P. Chang, S. Huc, E. Darrouzet, S. Lindenthal, and T. Pourcher Comparison of expressed human and mouse sodium/iodide symporters reveals differences in transport properties and subcellular localization J. Endocrinol., April 1, 2008; 197(1): 95 - 109. [Abstract] [Full Text] [PDF] K. Hasegawa, C. Hu, T. Nakamura, J. D. Marks, S. J. Russell, and K.-W. Peng Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins J. Virol., December 1, 2007; 81(23): 13149 - 13157. [Abstract] [Full Text] [PDF] C. Liu, J. N. Sarkaria, C. A. Petell, G. Paraskevakou, P. J. Zollman, M. Schroeder, B. Carlson, P. A. Decker, W. Wu, C. D. James, et al. Combination of Measles Virus Virotherapy and Radiation Therapy Has Synergistic Activity in the Treatment of Glioblastoma Multiforme Clin. Cancer Res., December 1, 2007; 13(23): 7155 - 7165. [Abstract] [Full Text] [PDF] J. R. del Valle, P. Devaux, G. Hodge, N. J. Wegner, M. B. McChesney, and R. Cattaneo A Vectored Measles Virus Induces Hepatitis B Surface Antigen Antibodies While Protecting Macaques against Measles Virus Challenge J. Virol., October 1, 2007; 81(19): 10597 - 10605. [Abstract] [Full Text] [PDF] A. Goel, S. K. Carlson, K. L. Classic, S. Greiner, S. Naik, A. T. Power, J. C. Bell, and S. J. Russell Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV({Delta}51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene Blood, October 1, 2007; 110(7): 2342 - 2350. [Abstract] [Full Text] [PDF] K. Hasegawa, T. Nakamura, M. Harvey, Y. Ikeda, A. Oberg, M. Figini, S. Canevari, L. C. Hartmann, and K.-W. Peng The Use of a Tropism-Modified Measles Virus in Folate Receptor-Targeted Virotherapy of Ovarian Cancer. Clin. Cancer Res., October 15, 2006; 12(20): 6170 - 6178. [Abstract] [Full Text] [PDF] G. Riesco-Eizaguirre and P. Santisteban A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512. [Abstract] [Full Text] [PDF] K. Hasegawa, L. Pham, M. K. O'Connor, M. J. Federspiel, S. J. Russell, and K.-W. Peng Dual therapy of ovarian cancer using measles viruses expressing carcinoembryonic antigen and sodium iodide symporter. Clin. Cancer Res., March 15, 2006; 12(6): 1868 - 1875. [Abstract] [Full Text] [PDF] T. Petrich, L. Quintanilla-Martinez, Z. Korkmaz, E. Samson, H. J. Helmeke, G. J. Meyer, W. H. Knapp, and E. Potter Effective Cancer Therapy with the {alpha}-Particle Emitter [211At]Astatine in a Mouse Model of Genetically Modified Sodium/Iodide Symporter-Expressing Tumors Clin. Cancer Res., February 15, 2006; 12(4): 1342 - 1348. [Abstract] [Full Text] [PDF] L. Heinzerling, V. Kunzi, P. A. Oberholzer, T. Kundig, H. Naim, and R. Dummer Oncolytic measles virus in cutaneous T-cell lymphomas mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells Blood, October 1, 2005; 106(7): 2287 - 2294. [Abstract] [Full Text] [PDF] D. J. Buchsbaum, T. R. Chaudhuri, and K. R. Zinn Radiotargeted Gene Therapy J. Nucl. Med., January 1, 2005; 46(1_suppl): 179S - 186S. [Abstract] [Full Text] [PDF] B. D. Anderson, T. Nakamura, S. J. Russell, and K.-W. Peng High CD46 Receptor Density Determines Preferential Killing of Tumor Cells by Oncolytic Measles Virus Cancer Res., July 15, 2004; 64(14): 4919 - 4926. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020